Skip to main content

Table 3 Radiobiological modeling results for tumor control probability and normal tissue complication probability across competing dose-fractionation regimens

From: Stereotactic ablative radiotherapy for ultra-central lung tumors: prioritize target coverage or organs at risk?

Outcome PTV coverage prioritized OAR constraints prioritized
50 Gy in 5 60 Gy in 8 60 Gy in 15 50 Gy in 5 60 Gy in 8 60 Gy in 15
tumor control 92.9 (89.7–99.1) 92.4 (84.7–95.3) 52.0 (48.3–55.7) 60.3 (31.5–80.1) 65.7 (39.2–81.4) 47.8 (41.0–53.3)
acute esophagitis ≥ grade 2 1.18 (0.45–3.98) 1.05 (0.44–2.44) 0.86 (0.42–1.85) 0.72 (0.34–1.35) 0.77 (0.39–1.40) 0.72 (0.42–1.49)
symptomatic pneumonitis (all grades) 4.30 (1.79–11.6) 4.09 (1.90–11.1) 3.68 (1.53–13.8) 3.44 (2.24–8.03) 3.45 (1.75–8.08) 2.97 (1.54–6.84)
pericarditis or pericardial effusion 0.01 (0.00–0.08) 0.00 (0.00–0.00) 0.00 (0.00–0.00) 0.00 (0.00–0.00) 0.00 (0.00–0.00) 0.00 (0.00–0.00)
proximal bronchial tree toxicity (grade 4 or 5) 49.7 (15.0–70.0a) 42.7 (5.0–70.0a) 4.0 (0.0–10.0) 0.0 (0.0–0.0) 0.0 (0.00–0.0) 1.3 (0.0–5.0)
uncomplicated tumor control 46.7 (27.6–77.6) 53.5 (25.4–90.4) 49.9 (44.6–54.0) 60.3 (31.5–80.1) 65.7 (39.2–81.4) 47.2 (41.0–52.8)
  1. Cells are average (range) tumor control probability or normal tissue complication probability (%). a4 cases had an EQD2 greater than the range presented by Cannon et al and it is therefore likely that their risk is greater than 70%